386 related articles for article (PubMed ID: 21768374)
1. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.
Olesen ET; Rützler MR; Moeller HB; Praetorius HA; Fenton RA
Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12949-54. PubMed ID: 21768374
[TBL] [Abstract][Full Text] [Related]
2. The vasopressin type 2 receptor and prostaglandin receptors EP2 and EP4 can increase aquaporin-2 plasma membrane targeting through a cAMP-independent pathway.
Olesen ET; Moeller HB; Assentoft M; MacAulay N; Fenton RA
Am J Physiol Renal Physiol; 2016 Nov; 311(5):F935-F944. PubMed ID: 27558562
[TBL] [Abstract][Full Text] [Related]
3. Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts.
Gao M; Cao R; Du S; Jia X; Zheng S; Huang S; Han Q; Liu J; Zhang X; Miao Y; Kang J; Gustafsson JÅ; Guan Y
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8397-402. PubMed ID: 26100911
[TBL] [Abstract][Full Text] [Related]
4. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus.
Li JH; Chou CL; Li B; Gavrilova O; Eisner C; Schnermann J; Anderson SA; Deng CX; Knepper MA; Wess J
J Clin Invest; 2009 Oct; 119(10):3115-26. PubMed ID: 19729836
[TBL] [Abstract][Full Text] [Related]
5. The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment.
Tamma G; Di Mise A; Ranieri M; Geller A; Tamma R; Zallone A; Valenti G
J Cell Mol Med; 2017 Sep; 21(9):1767-1780. PubMed ID: 28326667
[TBL] [Abstract][Full Text] [Related]
6. Activation of AQP2 water channels by protein kinase A: therapeutic strategies for congenital nephrogenic diabetes insipidus.
Ando F
Clin Exp Nephrol; 2021 Oct; 25(10):1051-1056. PubMed ID: 34224008
[TBL] [Abstract][Full Text] [Related]
7. Activation of AQP2 water channels without vasopressin: therapeutic strategies for congenital nephrogenic diabetes insipidus.
Ando F; Uchida S
Clin Exp Nephrol; 2018 Jun; 22(3):501-507. PubMed ID: 29478202
[TBL] [Abstract][Full Text] [Related]
8. Physiological insights into novel therapies for nephrogenic diabetes insipidus.
Sands JM; Klein JD
Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1149-F1152. PubMed ID: 27534996
[TBL] [Abstract][Full Text] [Related]
9. Psychotropic drugs upregulate aquaporin-2 via vasopressin-2 receptor/cAMP/protein kinase A signaling in inner medullary collecting duct cells.
Kim S; Jo CH; Kim GH
Am J Physiol Renal Physiol; 2021 May; 320(5):F963-F971. PubMed ID: 33843270
[TBL] [Abstract][Full Text] [Related]
10. AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus.
Ando F; Mori S; Yui N; Morimoto T; Nomura N; Sohara E; Rai T; Sasaki S; Kondo Y; Kagechika H; Uchida S
Nat Commun; 2018 Apr; 9(1):1411. PubMed ID: 29650969
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of prostaglandin E(2) on the migration of nasal fibroblasts.
Shin JM; Park IH; Moon YM; Hong SM; Cho JS; Um JY; Lee HM
Am J Rhinol Allergy; 2014; 28(3):e120-4. PubMed ID: 24980222
[TBL] [Abstract][Full Text] [Related]
12. Updates and Perspectives on Aquaporin-2 and Water Balance Disorders.
Noda Y; Sasaki S
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884753
[TBL] [Abstract][Full Text] [Related]
13. Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary concentration.
Bouley R; Lu HA; Nunes P; Da Silva N; McLaughlin M; Chen Y; Brown D
J Am Soc Nephrol; 2011 Jan; 22(1):59-72. PubMed ID: 21071524
[TBL] [Abstract][Full Text] [Related]
14. Genetic deletion of the nuclear factor of activated T cells 5 in collecting duct principal cells causes nephrogenic diabetes insipidus.
Petrillo F; Chernyakov D; Esteva-Font C; Poulsen SB; Edemir B; Fenton RA
FASEB J; 2022 Nov; 36(11):e22583. PubMed ID: 36197017
[TBL] [Abstract][Full Text] [Related]
15. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
Robben JH; Kortenoeven ML; Sze M; Yae C; Milligan G; Oorschot VM; Klumperman J; Knoers NV; Deen PM
Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12195-200. PubMed ID: 19587238
[TBL] [Abstract][Full Text] [Related]
16. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
[TBL] [Abstract][Full Text] [Related]
17. Aquaporin 2 (AQP2) and vasopressin type 2 receptor (V2R) endocytosis in kidney epithelial cells: AQP2 is located in 'endocytosis-resistant' membrane domains after vasopressin treatment.
Bouley R; Hawthorn G; Russo LM; Lin HY; Ausiello DA; Brown D
Biol Cell; 2006 Apr; 98(4):215-32. PubMed ID: 16563128
[TBL] [Abstract][Full Text] [Related]
18. A mini-review of pharmacological strategies used to ameliorate polyuria associated with X-linked nephrogenic diabetes insipidus.
Mortensen LA; Bistrup C; Jensen BL; Hinrichs GR
Am J Physiol Renal Physiol; 2020 Nov; 319(5):F746-F753. PubMed ID: 32924547
[TBL] [Abstract][Full Text] [Related]
19. Regulation of aquaporin-2 trafficking.
Nedvetsky PI; Tamma G; Beulshausen S; Valenti G; Rosenthal W; Klussmann E
Handb Exp Pharmacol; 2009; (190):133-57. PubMed ID: 19096775
[TBL] [Abstract][Full Text] [Related]
20. Prostaglandin E2 promotes proliferation of skeletal muscle myoblasts via EP4 receptor activation.
Mo C; Zhao R; Vallejo J; Igwe O; Bonewald L; Wetmore L; Brotto M
Cell Cycle; 2015; 14(10):1507-16. PubMed ID: 25785867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
